Last reviewed · How we verify

NCT04296201

Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology

Completed NA Last updated 17 February 2021
What this trial tests

NA trial testing DMA treatment in Skin Laxity in 15 participants. Completed in 15 February 2021.

Timeline
1 September 2020
Primary endpoint
15 February 2021
15 February 2021

Quick facts

Lead sponsorLumenis Be Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment15
Start date1 September 2020
Primary completion15 February 2021
Estimated completion15 February 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Lumenis Be Ltd. — full company profile →

Who can join

Adults 25 to 45, any sex, with Skin Laxity or Muscle Contracture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of at least 15 and up to 17 healthy subjects at a single site, aged 25-45 years old, who wish to receive a lifting effect and improved muscle definition, will be included in the study. The procedure will include treatments with the Legend Pro™ DMA™ technology. Photos will be obtained at pre-defined time points throughout the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Skin Laxity

Currently open trials in the same condition.

Other Lumenis Be Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04296201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing